Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.34 |
| ▸ | ALPG | P10696 | 2/20 | 0.31 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930749 | 0.88 | FPR2 (0.42) | FPR2ALPGPLAAOPRD1OPRK1 | |
| SCHEMBL11937134 | 0.87 | FPR2 (0.34) | FPR2ALPGPLAAOPRD1OPRK1 | |
| SCHEMBL11930753 | 0.87 | FPR2 (0.40) | FPR2ALPGPLAAOPRD1OPRK1 | |
| SCHEMBL11930718 | 0.85 | ALPG (0.33) | FPR2ALPGPLAAALPLKDM4E | |
| SCHEMBL10260881 | 0.83 | KDM4E (0.40) | FPR2ALPGPLAAALPLKDM4E | |
| SCHEMBL13341028 | 0.82 | FPR2 (0.36) | FPR2ALPGPLAAALPL | |
| SCHEMBL10261192 | 0.82 | POLB (0.41) | FPR2ALPGPLAAALPLKDM4E | |
| SCHEMBL2834770 | 0.80 | TBXAS1 (0.31) | FPR2 | |
| SCHEMBL11930712 | 0.80 | ALPG (0.37) | FPR2ALPGPLAAOPRK1ALPL | |
| SCHEMBL1742304 | 0.80 | FPR2 (0.32) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | FPR2 4575/4885ALPG 941/4885PLAA 1516/4885 |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | SLC6A7, DNPEP, PREP | FPR2 3813/4885ALPG 2197/4885PLAA 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.